Why Exclusive Licenses Destroy More Value Than They Create

Exclusive licenses feel like wins. The university gets a committed partner. The company gets protected market position. The inventor gets royalties. Everyone shakes hands and calls it a success.

Photo by Pixabay on Pexels.

Except, six years later, the technology is still sitting on a shelf.

This happens more than the field likes to admit. Exclusive licenses, especially broad, long-term ones granted to a single company early in a technology's development, are one of the most reliable ways to accidentally quarantine a promising invention. The deal looks clean at signing. The dysfunction shows up later, quietly, in a way that's hard to attribute to any single decision.

Here's the core problem: exclusivity hands the licensee a monopoly on action. If they don't move fast enough, don't have the right capabilities, or pivot their business strategy, the technology goes nowhere, and the university has no legal leverage to do anything about it. Performance milestones exist in theory. In practice, licensees are often sophisticated enough to hit the technical letter of a milestone without actually developing the market. "We filed a regulatory pre-submission" counts as progress. Whether anyone bought the product doesn't.

The incentive structure deserves scrutiny here. A large corporation licensing a university technology exclusively may be doing so not to commercialize it, but to keep it off the market. This isn't paranoia, it's documented strategy in pharma, ag-biotech, and materials science. Companies acquire exclusive rights to technologies adjacent to their core products specifically to prevent disruption. The university gets paid. The technology gets buried. Everyone complied with the contract.

Smaller licensees have different problems. An early-stage startup taking an exclusive license on broad IP often can't afford to develop the full scope of what they've licensed. They focus on the one application that fits their funding pitch, leaving three other use cases dormant for years. When they eventually fail or pivot, the license reverts, if the university was smart enough to include reversion clauses, but the clock has run, the market has moved, and the window may have closed.

Non-exclusive licensing doesn't solve everything. Some technologies genuinely require exclusivity to attract investment; no pharma company will spend $800 million on clinical trials without patent exclusivity. That logic is real. But it applies to a narrow slice of university IP, mostly late-stage, high-development-cost therapeutic assets. It gets incorrectly applied everywhere else.

What works better, more often than people try it, is field-of-use exclusive licensing. Grant exclusivity within a defined application domain, say, agricultural sensors, while preserving rights in adjacent fields like environmental monitoring or industrial IoT. The licensee gets the protection they need to justify investment. The university retains the ability to find other partners for other markets. You're not giving away the whole asset for the price of one application.

A diagram helps clarify the decision logic:

graph TD
    A{High dev cost + single market?} -->|Yes| B[Broad exclusive may be justified]
    A -->|No| C{Multiple potential markets?}
    C -->|Yes| D[Field-of-use exclusive per market]
    C -->|No| E{Early stage technology?}
    E -->|Yes| F[Option agreement first]
    E -->|No| G[Non-exclusive with performance terms]

Performance milestones also need rethinking. Most are written as technical checkboxes: complete a prototype, file an IND, reach a certain revenue threshold. What they rarely include is market development activity, distribution agreements signed, pilot customers engaged, sales infrastructure built. A licensee can satisfy every technical milestone and still never intend to sell anything. Milestones should be tied to commercial traction, not just engineering progress.

There's a harder conversation underneath all of this. Many tech transfer offices default to exclusive licenses because companies demand them, and companies are the ones with money. Saying no to exclusivity, or insisting on narrower terms, feels like risking the deal. Sometimes it is. But the alternative is a portfolio full of technically licensed technologies that never reach patients, farmers, manufacturers, or anyone else who could use them.

The metric that matters isn't licenses executed. It's technologies deployed.

Exclusivity is a tool, not a default. Used precisely, in the right situations, it gets important technologies funded and built. Used reflexively, it turns university IP into a holding pen. Most offices know the difference. The pressure to close deals makes it easy to ignore.